AB 269: Public health: COVID-19 testing and dispensing sites.
- Session Year: 2023-2024
- House: Assembly
- Latest Version Date: 2023-03-02
Current Status:
Passed
(2023-03-03: Chaptered by Secretary of State - Chapter 1, Statutes of 2023.)
Introduced
In Committee
First Chamber
In Committee
Second Chamber
Enacted
Existing law, the California Emergency Services Act, authorizes the Governor to declare a state of emergency during conditions of disaster or extreme peril to persons or property, including epidemics. Pursuant to this authority, on March 4, 2020, the Governor declared a state of emergency relating to the novel coronavirus 2019 (COVID-19) pandemic, and ordered, among other things, that the certification and licensure requirements as specified in statute and regulation be suspended to all persons who meet the requirements under the Clinical Laboratory Improvement Amendments (CLIA) for high complexity testing and who are performing analysis of samples to test for SARS-CoV-2, the virus that causes COVID-19, in any certified public health laboratory or licensed clinical laboratory, and that the California Health and Human Services Agency is required to identify and make available medical facilities and other facilities that are suitable for use as medical facilities as necessary for treating individuals who test positive for COVID-19.
This bill would authorize a person to perform an analysis of samples to test for SARS-CoV-2 in a clinical laboratory or a city, county, or city and county public health laboratory if they meet the requirements under CLIA for high complexity testing. The bill would, until January 1, 2024, authorize an entity contracted with and approved by the State Department of Public Health to operate a designated COVID-19 testing and dispensing site to acquire, dispense, and store COVID-19 oral therapeutics, as defined, at or from a designated site.
This bill would declare that it is to take effect immediately as an urgency statute.
Existing law, the California Emergency Services Act, authorizes the Governor to declare a state of emergency during conditions of disaster or extreme peril to persons or property, including epidemics. Pursuant to this authority, on March 4, 2020, the Governor declared a state of emergency relating to the novel coronavirus 2019 (COVID-19) pandemic, and ordered, among other things, that the certification and licensure requirements as specified in statute and regulation be suspended to all persons who meet the requirements under the Clinical Laboratory Improvement Amendments (CLIA) for high complexity testing and who are performing analysis of samples to test for SARS-CoV-2, the virus that causes COVID-19, in any certified public health laboratory or licensed clinical laboratory, and that the California Health and Human Services Agency is required to identify and make available medical facilities and other facilities that are suitable for use as medical facilities as necessary for treating individuals who test positive for COVID-19.
This bill would authorize a person to perform an analysis of samples to test for SARS-CoV-2 in a clinical laboratory or a city, county, or city and county public health laboratory if they meet the requirements under CLIA for high complexity testing. The bill would, until January 1, 2024, authorize an entity contracted with and approved by the State Department of Public Health to operate a designated COVID-19 testing and dispensing site to acquire, dispense, and store COVID-19 oral therapeutics, as defined, at or from a designated site.
This bill would declare that it is to take effect immediately as an urgency statute.
Existing law, the California Emergency Services Act, authorizes the Governor to declare a state of emergency during conditions of disaster or extreme peril to persons or property, including epidemics. Pursuant to this authority, on March 4, 2020, the Governor declared a state of emergency relating to the novel coronavirus 2019 (COVID-19) pandemic, and ordered, among other things, that the certification and licensure requirements as specified in statute and regulation be suspended to all persons who meet the requirements under the Clinical Laboratory Improvement Amendments (CLIA) for high complexity testing and who are performing analysis of samples to test for SARS-CoV-2, the virus that causes COVID-19, in any certified public health laboratory or licensed clinical laboratory, and that the California Health and Human Services Agency is required to identify and make available medical facilities and other facilities that are suitable for use as medical facilities as necessary for treating individuals who test positive for COVID-19.
This bill would authorize a person to perform an analysis of samples to test for SARS-CoV-2 in a clinical laboratory or a city, county, or city and county public health laboratory if they meet the requirements under CLIA for high complexity testing. The bill would, until January 1, 2024, authorize an entity contracted with and approved by the State Department of Public Health to operate a designated COVID-19 testing and dispensing site to acquire, dispense, and store COVID-19 oral therapeutics, as defined, at or from a designated site.
This bill would declare that it is to take effect immediately as an urgency statute.
Existing law, the California Emergency Services Act, authorizes the Governor to declare a state of emergency during conditions of disaster or extreme peril to persons or property, including epidemics. Pursuant to this authority, on March 4, 2020, the Governor declared a state of emergency relating to the novel coronavirus 2019 (COVID-19) pandemic, and ordered, among other things, that the certification and licensure requirements as specified in statute and regulation be suspended to all persons who meet the requirements under the Clinical Laboratory Improvement Amendments (CLIA) for high complexity testing and who are performing analysis of samples to test for SARS-CoV-2, the virus that causes COVID-19, in any certified public health laboratory or licensed clinical laboratory, and that the California Health and Human Services Agency is required to identify and make available medical facilities and other facilities that are suitable for use as medical facilities as necessary for treating individuals who test positive for COVID-19.
This bill would authorize a person to perform an analysis of samples to test for SARS-CoV-2 in a clinical laboratory or a city, county, or city and county public health laboratory if they meet the requirements under CLIA for high complexity testing. The bill would, until January 1, 2024, authorize an entity approved by the State Department of Public Health to operate a designated COVID-19 testing and dispensing site to acquire, dispense, and store COVID-19 oral therapeutics, as defined, at or from a designated site.
This bill would declare that it is to take effect immediately as an urgency statute.
Notwithstanding Section 1206.5, a person may perform an analysis of samples to test for SARS-CoV-2, the virus that causes COVID-19, in a clinical laboratory if they meet the requirements under the Clinical Laboratory Improvement Amendments in Section 493.1489 of Title 42 of the Code of Federal Regulations for high complexity testing.
SEC. 2.Section 4176 is added to the Business and Professions Code, to read:4176.(a)Notwithstanding any other law, an entity contracted with and approved by the State Department of Public Health to operate a designated COVID-19 testing and dispensing site may acquire, dispense, and store COVID-19 oral therapeutics at or from a designated site. COVID-19 oral therapeutics shall be stored in a secure manner, as determined by the State Department of Public Health. Nothing in this chapter shall prohibit the distribution of COVID-19 oral therapeutics to, or acquisition by, an approved entity or a designated site.
(b)A prescribing physician, or a registered nurse under the direction of such physician, may dispense COVID-19 oral therapeutics to patients at a designated site.
(c)COVID-19 oral therapeutics that are packaged by the manufacturer in a dispensable container shall be dispensed in the original manufacturers container. Each COVID-19 oral therapeutic dispensed shall be labeled as specified in paragraphs (1), (2), (3), (4), (5), (7), (8), and (9) of subdivision (a) of Section 4076. The label shall also include the address of the designated site where the therapeutic is dispensed.
(d)An entity contracted with and approved by the department to operate a designated site pursuant to subdivision (a) shall maintain for three years records of acquisition and disposition for each site, including the kind and amounts of COVID-19 oral therapeutics dispensed at each site and for each patient. The records shall be available for inspection by the State Department of Public Health and the board.
(e)For purposes of this section, COVID-19 oral therapeutics means drugs that are approved or authorized by the United States Food and Drug Administration for the treatment of COVID-19 and administered orally.
(f)This section shall remain in effect only until January 1, 2024, and as of that date is repealed.
SEC. 3.Section 101161 is added to the Health and Safety Code, to read:101161.A person may perform an analysis of samples to test for SARS-CoV-2, the virus that causes COVID-19, in any city or county public health laboratory if they meet the requirements under the Clinical Laboratory Improvement Amendments in Section 493.1489 of Title 42 of the Code of Federal Regulations for high complexity testing.
SEC. 4.This act is an urgency statute necessary for the immediate preservation of the public peace, health, or safety within the meaning of Article IV of the California Constitution and shall go into immediate effect. The facts constituting the necessity are:
In order to ensure the continued ability of nurses to dispense COVID-19 therapeutics as part of the Test to Treat Program and address the technical qualifications of laboratory workers allowing them to solely process COVID-19 tests, it is necessary that this act take effect immediately.
Notwithstanding Section 1206.5, a person may perform an analysis of samples to test for SARS-CoV-2, the virus that causes COVID-19, in a clinical laboratory if they meet the requirements under the Clinical Laboratory Improvement Amendments in Section 493.1489 of Title 42 of the Code of Federal Regulations for high complexity testing.
SEC. 2.Section 4176 is added to the Business and Professions Code, to read:4176.(a)Notwithstanding any other law, an entity contracted with and approved by the State Department of Public Health to operate a designated COVID-19 testing and dispensing site may acquire, dispense, and store COVID-19 oral therapeutics at or from a designated site. COVID-19 oral therapeutics shall be stored in a secure manner, as determined by the State Department of Public Health. Nothing in this chapter shall prohibit the distribution of COVID-19 oral therapeutics to, or acquisition by, an approved entity or a designated site.
(b)A prescribing physician, or a registered nurse under the direction of such physician, may dispense COVID-19 oral therapeutics to patients at a designated site.
(c)COVID-19 oral therapeutics that are packaged by the manufacturer in a dispensable container shall be dispensed in the original manufacturers container. Each COVID-19 oral therapeutic dispensed shall be labeled as specified in paragraphs (1), (2), (3), (4), (5), (7), (8), and (9) of subdivision (a) of Section 4076. The label shall also include the address of the designated site where the therapeutic is dispensed.
(d)An entity contracted with and approved by the department to operate a designated site pursuant to subdivision (a) shall maintain for three years records of acquisition and disposition for each site, including the kind and amounts of COVID-19 oral therapeutics dispensed at each site and for each patient. The records shall be available for inspection by the State Department of Public Health and the board.
(e)For purposes of this section, COVID-19 oral therapeutics means drugs that are approved or authorized by the United States Food and Drug Administration for the treatment of COVID-19 and administered orally.
(f)This section shall remain in effect only until January 1, 2024, and as of that date is repealed.
SEC. 3.Section 101161 is added to the Health and Safety Code, to read:101161.A person may perform an analysis of samples to test for SARS-CoV-2, the virus that causes COVID-19, in any city or county public health laboratory if they meet the requirements under the Clinical Laboratory Improvement Amendments in Section 493.1489 of Title 42 of the Code of Federal Regulations for high complexity testing.
SEC. 4.This act is an urgency statute necessary for the immediate preservation of the public peace, health, or safety within the meaning of Article IV of the California Constitution and shall go into immediate effect. The facts constituting the necessity are:
In order to ensure the continued ability of nurses to dispense COVID-19 therapeutics as part of the Test to Treat Program and address the technical qualifications of laboratory workers allowing them to solely process COVID-19 tests, it is necessary that this act take effect immediately.
Notwithstanding Section 1206.5, a person may perform an analysis of samples to test for SARS-CoV-2, the virus that causes COVID-19, in a clinical laboratory if they meet the requirements under the Clinical Laboratory Improvement Amendments in Section 493.1489 of Title 42 of the Code of Federal Regulations for high complexity testing.
SEC. 2.Section 4176 is added to the Business and Professions Code, to read:4176.(a)Notwithstanding any other law, an entity contracted with and approved by the State Department of Public Health to operate a designated COVID-19 testing and dispensing site may acquire, dispense, and store COVID-19 oral therapeutics at or from a designated site. COVID-19 oral therapeutics shall be stored in a secure manner, as determined by the State Department of Public Health. Nothing in this chapter shall prohibit the distribution of COVID-19 oral therapeutics to, or acquisition by, an approved entity or a designated site.
(b)A prescribing physician, or a registered nurse under the direction of such physician, may dispense COVID-19 oral therapeutics to patients at a designated site.
(c)COVID-19 oral therapeutics that are packaged by the manufacturer in a dispensable container shall be dispensed in the original manufacturers container. Each COVID-19 oral therapeutic dispensed shall be labeled as specified in paragraphs (1), (2), (3), (4), (5), (7), (8), and (9) of subdivision (a) of Section 4076. The label shall also include the address of the designated site where the therapeutic is dispensed.
(d)An entity contracted with and approved by the department to operate a designated site pursuant to subdivision (a) shall maintain for three years records of acquisition and disposition for each site, including the kind and amounts of COVID-19 oral therapeutics dispensed at each site and for each patient. The records shall be available for inspection by the State Department of Public Health and the board.
(e)For purposes of this section, COVID-19 oral therapeutics means drugs that are approved or authorized by the United States Food and Drug Administration for the treatment of COVID-19 and administered orally.
(f)This section shall remain in effect only until January 1, 2024, and as of that date is repealed.
SEC. 3.Section 101161 is added to the Health and Safety Code, to read:101161.A person may perform an analysis of samples to test for SARS-CoV-2, the virus that causes COVID-19, in any city or county public health laboratory if they meet the requirements under the Clinical Laboratory Improvement Amendments in Section 493.1489 of Title 42 of the Code of Federal Regulations for high complexity testing.
SEC. 4.This act is an urgency statute necessary for the immediate preservation of the public peace, health, or safety within the meaning of Article IV of the California Constitution and shall go into immediate effect. The facts constituting the necessity are:
In order to ensure the continued ability of nurses to dispense COVID-19 therapeutics as part of the Test to Treat Program and address the technical qualifications of laboratory workers allowing them to solely process COVID-19 tests, it is necessary that this act take effect immediately.
Notwithstanding Section 1206.5, a person may perform an analysis of samples to test for SARS-CoV-2, the virus that causes COVID-19, in a clinical laboratory if they meet the requirements under the Clinical Laboratory Improvement Amendments in Section 493.1489 of Title 42 of the Code of Federal Regulations for high complexity testing.
SEC. 2.Section 4176 is added to the Business and Professions Code, to read:4176.(a)Notwithstanding any other law, an entity approved by the State Department of Public Health to operate a designated COVID-19 testing and dispensing site may acquire, dispense, and store COVID-19 oral therapeutics at or from a designated site. COVID-19 oral therapeutics shall be stored in a secure manner, as determined by the State Department of Public Health. Nothing in this chapter shall prohibit the distribution of COVID-19 oral therapeutics to, or acquisition by, an approved entity or a designated site.
(b)A prescribing physician, or a registered nurse under the direction of such physician, may dispense COVID-19 oral therapeutics to patients at a designated site.
(c)COVID-19 oral therapeutics that are packaged by the manufacturer in a dispensable container shall be dispensed in the original manufacturers container. Each COVID-19 oral therapeutic dispensed shall be labeled as specified in paragraphs (1), (2), (3), (4), (5), (7), (8), and (9) of subdivision (a) of Section 4076. The label shall also include the address of the designated site where the therapeutic is dispensed.
(d)An entity approved to operate a designated site pursuant to subdivision (a) shall maintain for three years records of acquisition and disposition for each site, including the kind and amounts of COVID-19 oral therapeutics dispensed at each site and for each patient. The records shall be available for inspection by the State Department of Public Health and the board.
(e)For purposes of this section, COVID-19 oral therapeutics means drugs that are approved or authorized by the United States Food and Drug Administration for the treatment of COVID-19 and administered orally.
(f)This section shall remain in effect only until January 1, 2024, and as of that date is repealed.
SEC. 3.Section 101161 is added to the Health and Safety Code, to read:101161.A person may perform an analysis of samples to test for SARS-CoV-2, the virus that causes COVID-19, in any city or county public health laboratory if they meet the requirements under the Clinical Laboratory Improvement Amendments in Section 493.1489 of Title 42 of the Code of Federal Regulations for high complexity testing.
SEC. 4.This act is an urgency statute necessary for the immediate preservation of the public peace, health, or safety within the meaning of Article IV of the California Constitution and shall go into immediate effect. The facts constituting the necessity are:
In order to ensure the continued ability of nurses to dispense COVID-19 therapeutics as part of the Test to Treat Program and address the technical qualifications of laboratory workers allowing them to solely process COVID-19 tests, it is necessary that this act take effect immediately.
|
Date
|
Status
|
|---|---|
| Mar 3, 2023 | Chaptered by Secretary of State - Chapter 1, Statutes of 2023. |
| Mar 2, 2023 | Approved by the Governor. |
| Mar 2, 2023 | Enrolled and presented to the Governor at 10:30 a.m. |
| Mar 2, 2023 | In Assembly. Ordered to Engrossing and Enrolling. |
| Mar 2, 2023 | Read third time. Urgency clause adopted. Passed. Ordered to the Assembly. (Ayes 34. Noes 0. Page 281.). |
| Mar 1, 2023 | Read second time. Ordered to third reading. |
| Feb 28, 2023 | From committee: Be ordered to second reading pursuant to Senate Rule 28.8. |
| Feb 28, 2023 | From committee: Do pass and re-refer to Com. on APPR. (Ayes 10. Noes 0.) (February 27). Re-referred to Com. on APPR. |
| Feb 22, 2023 | Referred to Com. on B., P. & E. D. |
| Feb 17, 2023 | In Senate. Read first time. To Com. on RLS. for assignment. |
| Feb 17, 2023 | Read third time. Urgency clause adopted. Passed. Ordered to the Senate. (Ayes 69. Noes 0. Page 402.). |
| Feb 16, 2023 | Read second time. Ordered to third reading. |
| Feb 15, 2023 | From committee: Do pass. (Ayes 11. Noes 0.) (February 15). |
| Feb 14, 2023 | From committee: Do pass and re-refer to Com. on HEALTH. (Ayes 17. Noes 0.) (February 14). Re-referred to Com. on HEALTH. |
| Feb 9, 2023 | Re-referred to Com. on B. & P. |
| Feb 8, 2023 | From committee chair, with author's amendments: Amend, and re-refer to Com. on B. & P. Read second time and amended. |
| Feb 6, 2023 | Assembly Rule 56 suspended. (Page 283.) |
| Feb 6, 2023 | (pending re-refer to Com. on HEALTH) |
| Feb 6, 2023 | Joint Rule 55 suspended. (Ayes 79. Noes 0. Page 283.) |
| Feb 6, 2023 | Art. IV, Sec. 8(a) of the Constitution dispensed with. (Ayes 79. Noes 0. Page 282.) |
| Feb 2, 2023 | Referred to Com. on B. & P. |
| Jan 24, 2023 | From printer. May be heard in committee February 23. |
| Jan 23, 2023 | Read first time. To print. |
|
Date
|
Description
|
Location
|
Votes
|
|
|---|---|---|---|---|
| Mar 2, 2023 | Assembly 3rd Reading AB269 Berman By Limón Urgency Clause | Senate Floor |
Passed |
|
| Feb 27, 2023 | Do pass, but first be re-referred to the Committee on [Appropriations] | Senate Standing Committee on Business, Professions and Economic Development |
Passed |
|
| Feb 17, 2023 | AB 269 Berman Third Reading Urgency | Assembly Floor |
Passed |
|
| Feb 15, 2023 | Do pass. | Assembly Standing Committee on Health |
Passed |
|
| Feb 14, 2023 | Do pass and be re-referred to the Committee on [Health] | Assembly Standing Committee on Business and Professions |
Passed |
This list shows positions taken on this bill by organizations on the date displayed, which is linked to the original source.
Positions by individuals are not included.
|
Organization
|
Position
|
Date
|
|---|---|---|
| California Association For Medical Laboratory Technology | ** Against | |
| California Association Of Public Health Laboratory Directors | ** Support | |
| California Clinical Laboratory Association | ** Support | |
| California Pan-Ethnic Health Network | ** Support | |
| County Health Executives Association Of California | ** Support | |
| Health Officers Association Of California | ** Support | |
| Quest Diagnostics | ** Support | |
| The California Association of Medical Laboratory Technology | ** Against |
SENATE RULES COMMITTEE Office of Senate Floor Analyses (916) 651-1520 Fax: (916) 327-4478 | AB 269 |
THIRD READING
Bill No: AB 269
Author: Berman (D)
Amended: 2/8/23 in Assembly
Vote: 27 - Urgency
SENATE BUS., PROF. & ECON. DEV. COMMITTEE: 10-0, 2/27/23
AYES: Roth, Alvarado-Gil, Archuleta, Ashby, Becker, Dodd, Niello, Smallwood-Cuevas, Wahab, Wilk
NO VOTE RECORDED: Nguyen, Eggman, Glazer
SENATE APPROPRIATIONS COMMITTEE: Senate Rule 28.8
ASSEMBLY FLOOR: 69-0, 2/17/23 - See last page for vote
SUBJECT: Public health: COVID-19 testing and dispensing sites
SOURCE: Author
DIGEST:
This bill authorizes a person to perform an analysis of samples to test for SARS-CoV-2, the virus that causes COVID-19, in a clinical laboratory or a city, county, or city and county public health laboratory if they meet certain requirements. This bill also authorizes an entity contracted with and approved by the California Department of Public Health (CDPH) to operate a designated COVID-19 testing and dispensing site to acquire, dispense, and store COVID-19 oral therapeutics, as defined, at or from a designated site, until January 1, 2024.
ANALYSIS:
Existing law:
- Prohibits a person from performing a clinical laboratory test or examination classified as waived under the federal Clinical Laboratory Improvement Amendments of 1988 (42 U.S.C. Sec. 263a; P.L. 100-578) and the regulations adopted thereunder by the federal Health Care Financing Administration and effective on January 1, 1994, or any later date (CLIA) unless the clinical laboratory test or examination is performed under the overall operation and administration of the laboratory director, according to specified provisions. CLIA waived tests are federally defined as simple laboratory examinations and procedures that are approved by the Food and Drug Administration (FDA) for home use, employ methodologies that are simple and accurate as to render the likelihood of erroneous results negligible or pose no reasonable risk of harm to the patient if the test is performed incorrectly. (Business and Professions Code (BPC) § 1206.5 and Health and Safety Code (HSC) § 101150)
- Requires any city or county public health laboratory, as specified, be approved by CDPH and comply with the requirements of CLIA, as specified. (HSC § 101160)
- Permits a pharmacist or a clinic licensed and acting under specified authority to, in good faith, furnish a dangerous drug or dangerous device in reasonable quantities without a prescription during a federal, state, or local emergency, to further the health and safety of the public. Permits, during a declared federal, state, or local emergency, the Board of Pharmacy (BOP) to waive application of any provisions of the Pharmacy Law or the regulations adopted pursuant to it if, in BOP’s opinion, the waiver will aid in the protection of public health or the provision of patient care. Permits BOP to continue to waive application of any provision of the Pharmacy Law for up to 90 days following the termination of the declared emergency if, in BOP’s opinion, the continued waiver will aid in the protection of the public health or in the provision of patient care. (BPC § 4062 (a) (b) and (d))
- Authorizes a registered nurse to dispense drugs or devices upon an order by a licensed physician and surgeon or other specified health professional if the registered nurse is functioning within a licensed primary care clinic. (BPC § 2725.1)
This bill:
- Authorizes a person to perform an analysis of samples to test for SARS-CoV-2, the virus that causes COVID-19, in a clinical laboratory or a city, county, or city and county public health laboratory if they meet the requirements under CLIA for high complexity testing, as specified.
- Authorizes an entity contracted with and approved by the CDPH to operate a designated COVID-19 testing and dispensing site to acquire, dispense, and store COVID-19 oral therapeutics, as defined, at or from a designated site, until January 1, 2024.
- States that this bill is an urgency measure as the state of California emergency declaration, which went into effect in March of 2020, is set to sunset on February 28, 2023, upon the State of Emergency ending, active waivers that were issued under the authority of the State of Emergency and Executive Orders will also expire.
Background
A facility that performs laboratory tests on human specimens for diagnosis or assessment must be certified under CLIA. CLIA certification requirements vary depending on the complexity of the laboratory tests performed. In general, the more complicated the test, the more stringent the requirements, including increased training and licensing of laboratory personnel. At a minimum, all laboratories must have a licensed clinical laboratory director. The FDA determines the complexity of CLIA laboratory tests. Waived tests are simple tests with a low risk for an incorrect result. While CLIA establishes minimum federal standards, it allows states to enact more stringent state law requirements.
Current law prohibits a prescriber from dispensing drugs or dangerous devices to patients in the prescriber’s office or place of practice without specified conditions being met. In the wake of the COVID-19 pandemic, federal and state governments expedited certain processes and waived certain requirements to protect the health and safety of the public. At the federal level, this meant providing emergency use authorizations for COVID-19 tests and vaccines.
In 2020, California undertook similar efforts to combat the COVID-19 pandemic. In March 2020, the Governor issued Executive Order N-25-20 (EO) to suspend statutes and regulations in support of the state’s pandemic response efforts. One part of the EO states:
“The certification and licensure requirements of California Code of Regulations, Title 17, section 1079 and Business and Professions Code section 1206.5 are suspended as to all persons who meet the requirements under the Clinical Laboratory Improvement Amendments of section 353 of the Public Health Service Act for high complexity testing and who are performing analysis of samples to test for SARS-CoV-2, the virus that causes COVID-19, in any certified public health laboratory or licensed clinical laboratory.”
Therefore, anyone who meets the CLIA requirements for high complexity testing can perform analyses of samples to test for SARS-CoV-2, the virus that causes COVID-19, in any certified public health laboratory or licensed clinical laboratory. Professionals who are able to perform these tests due to the waiver include a physician, podiatrist, dentist, naturopathic doctor, person licensed to engage in clinical laboratory practice or to direct a clinical lab, physician assistant, perfusionist, respiratory care practitioner, medical assistant, pharmacist, naturopathic assistant, licensed optometrist, other health care personnel providing direct patient care, any other person performing non-diagnostic testing, as specified. This expansion of professionals allowed for the increased staff required to support California through the COVID-19 pandemic.
Given that this EO’s authority relies on a Governor-issued state of emergency, and given that the Governor has stated that California’s COVID-19 state of emergency will end on February 28, 2023, the EO will no longer retain the force of law after this date.
CDPH currently approves OptumServe sites to offer antigen testing, telehealth prescribing for COVID-positive patients, and on-site Paxlovid and molnupiravir dispensing in one setting, as opposed to obtaining a prescription fill at an offsite traditional pharmacy.
Since a key aspect of the CDPH’s Test-to-Treat program at these sites involves dispensing therapeutics, the BOP waived Article 12 of Pharmacy Law which requires compliance with various requirements for storage and dispensing of drugs. Under its continued authority to issue waivers during a state of emergency, on April 19, 2022, the BOP issued a limited waiver applicable only to the CDPH, which waived specified statutory restrictions on entities operating a testing site approved by the CDPH to dispense COVID-19 oral therapeutics from state supplies, under specified conditions.
The BOP’s waiver also required Test-to-Treat sites to comply with a series of additional requirements relating to drug container labeling, storage, and recordkeeping. The BOP’s waiver was set to expire at the end of 2022; the waiver was subsequently extended on December 5, 2022. In the Governor’s October 2022 press release declaring the end of the State’s COVID-19 State of Emergency effective, February 28, 2023, the Governor noted, “To maintain California’s COVID-19 laboratory testing and therapeutics treatment capacity, the Newsom Administration will be seeking two statutory changes immediately upon the Legislature’s return: 1) The continued ability of nurses to dispense COVID-19 therapeutics; and 2) The continued ability of laboratory workers to solely process COVID-19 tests,” which this bill seeks to do.
Comments
Section 2 of this bill related to the dispensing of COVID-19 oral therapeutics will expire on January 1, 2024, likely because Test-to-Treat sites may no longer have the need to be operational by the end of the year. However, the provisions of this measure allowing a person to test for COVID-19 if they meet CLIA requirements in both clinical laboratory and city and county public health laboratory settings will extend beyond 2024 since they do not also include a sunset date. Given that it remains unclear whether the volume of testing for COVID-19 will remain the same over time as it has been for the past number of years during the State of Emergency, it may be appropriate for the authority provided in this measure to be reevaluated through the inclusion of a sunset date on all sections of the bill in order to allow for a thorough determination about the necessity of permanent authority to conduct these tests.
Further, while there is currently only one entity contracted with and approved by CDPH to provide services through the Test-to-Treat program, the drafting of this measure could potentially open the door for any contracted entities to operate without the protections outlined in the Pharmacy Law for drug acquisition, storage, and dispensing. It may be appropriate for this authority to be further narrowed to ensure additional entities beyond the unique settings providing important Test-to-Treat care defined in this bill are not potentially able to provide services outside of the traditional parameters outlined in Pharmacy Law.
FISCAL EFFECT: Appropriation: No Fiscal Com.: Yes Local: No
SUPPORT: (Verified 3/1/23)
California Association of Public Health Laboratory Directors
California Clinical Laboratory Association
California Pan-Ethnic Health Network
County Health Executives Association of California
Health Officers Association of California
Quest Diagnostics
OPPOSITION: (Verified 3/1/23)
None received
ARGUMENTS IN SUPPORT: Supporters note that as California moves beyond a State of Emergency, it is important to maintain tools in place to protect communities from COVID-19. Supporters also note that the measure will help laboratories meet testing demands in the face of workforce shortages and write that laboratories would be challenged to meet current and future needs without the waiver being extended through this bill.
ASSEMBLY FLOOR: 69-0, 2/17/23
AYES: Addis, Aguiar-Curry, Bains, Bauer-Kahan, Bennett, Berman, Boerner Horvath, Bonta, Bryan, Juan Carrillo, Wendy Carrillo, Cervantes, Chen, Connolly, Megan Dahle, Davies, Dixon, Essayli, Flora, Mike Fong, Friedman, Gabriel, Gallagher, Gipson, Haney, Hart, Holden, Hoover, Irwin, Jackson, Jones-Sawyer, Kalra, Lackey, Lee, Low, Lowenthal, Maienschein, Mathis, McCarty, Muratsuchi, Stephanie Nguyen, Ortega, Pacheco, Papan, Joe Patterson, Petrie-Norris, Quirk-Silva, Ramos, Reyes, Luz Rivas, Robert Rivas, Rodriguez, Blanca Rubio, Sanchez, Santiago, Schiavo, Soria, Ta, Ting, Valencia, Villapudua, Waldron, Wallis, Ward, Weber, Wilson, Wood, Zbur, Rendon
NO VOTE RECORDED: Alanis, Alvarez, Arambula, Calderon, Vince Fong, Garcia, Grayson, McKinnor, Jim Patterson, Pellerin, Wicks
Prepared by: Dana Shaker / B., P. & E.D. / , Elissa Silva / B., P. & E.D. /
3/1/23 13:56:45
**** END ****
SENATE COMMITTEE ON
BUSINESS, PROFESSIONS AND ECONOMIC DEVELOPMENT
Senator Richard Roth, Chair
2023 - 2024 Regular
Bill No: Hearing Date: 2/27/2023
Author: | |||
Version: |
| ||
Urgency: | Fiscal: | ||
Consultant: | |||
Subject:
SUMMARY:
Authorizes a person to perform an analysis of samples to test for SARS-CoV-2, the virus that causes COVID-19, in a clinical laboratory or a city, county, or city and county public health laboratory if they meet certain requirements. Authorizes an entity contracted with and approved by the California Department of Public Health (CDPH) to operate a designated COVID-19 testing and dispensing site to acquire, dispense, and store COVID-19 oral therapeutics, as defined, at or from a designated site, until January 1, 2024.
Existing law:
- Provides for the licensure, registration, and regulation of clinical laboratories and various clinical laboratory personnel by CDPH, with specified exceptions. (Business and Professions Code (BPC) § 1200-1327)
- Defines, for purposes of state regulation of clinical laboratories, the following:
- “CLIA” to mean the federal Clinical Laboratory Improvement Amendments of 1988 (42 U.S.C. Sec. 263a; P.L. 100-578) and the regulations adopted thereunder by the federal Health Care Financing Administration and effective on January 1, 1994, or any later date, when adopted in California pursuant to subdivision (b) of Section 1208. (BPC § 1202.5(a))
- “Clinical laboratory” to mean any place used, or any establishment or institution organized or operated, for the performance of clinical laboratory tests or examinations or the practical application of the clinical laboratory sciences. That application may include any means that applies the clinical laboratory sciences. (BPC § 1206(a)(8))
- Prohibits a person from performing a clinical laboratory test or examination classified as waived under CLIA unless the clinical laboratory test or examination is performed under the overall operation and administration of the laboratory director, as described in Section 1209, including, but not limited to, documentation by the laboratory director of the adequacy of the qualifications and competency of the personnel, and the test is performed by specified personnel. (BPC § 1206.5(a))
- States that no person shall perform clinical laboratory tests or examinations classified as of high complexity under CLIA unless the clinical laboratory test or examination is performed under the overall operation and administration of the laboratory director, where the test is performed by one of the following:
- a licensed physician and surgeon holding an M.D. or D.O. degree;
- a licensed podiatrist or a licensed dentist, as specified;
- a person licensed to engage in clinical laboratory practice or to direct a clinical laboratory, as specified;
- a person who supports a public health laboratory in the examination of specimens from suspected cases of infections and environmental diseases, that may include milk products, waters, and the environment, as specified;
- a licensed physician assistant, as specified;
- a perfusionist, as specified;
- a respiratory care practitioner, as specified;
- a person performing nuclear medicine technology, as specified;
- a person if performing blood gas analysis, as specified;
- any other person within a physician office laboratory if the test is performed under the onsite supervision of the patient’s physician and surgeon or a podiatrist who will: 1) ensure that the person is performing test methods as required for accurate and reliable tests; and 2) have personal knowledge of the results of clinical laboratory testing or examination performed by that person before the test results are reported from the laboratory. (BPC § 1206.5(c) and Health and Safety Code (HSC) § 101150)
- Requires any city or county public health laboratory, as specified, be approved by CDPH and comply with the requirements of CLIA, as specified. (HSC § 101160)
- Prohibits a prescriber from dispensing drugs or dangerous devices to patients in the prescriber’s office or place of practice unless specified conditions are met, where relevant business and professions boards share enforcement authority with the Board of Pharmacy (BOP), as specified, where other requirements and exceptions are qualified, as specified. (BPC § 4170 et seq.)
- Permits a pharmacist or a clinic licensed and acting under specified authority to, in good faith, furnish a dangerous drug or dangerous device in reasonable quantities without a prescription during a federal, state, or local emergency, to further the health and safety of the public. (BPC § 4062 (a))
- Permits, during a declared federal, state, or local emergency, the BOP to waive application of any provisions of the Pharmacy Law or the regulations adopted pursuant to it if, in BOP’s opinion, the waiver will aid in the protection of public health or the provision of patient care. (BPC § 4062 (b))
- Permits BOP to continue to waive application of any provision of the Pharmacy Law for up to 90 days following the termination of the declared emergency if, in BOP’s opinion, the continued waiver will aid in the protection of the public health or in the provision of patient care. (BPC § 4062 (d))
- Authorizes a registered nurse to dispense drugs or devices upon an order by a licensed physician and surgeon or other specified health professional if the registered nurse is functioning within a licensed primary care clinic. (BPC § 2725.1)
Existing Federal Law:
- Establishes CLIA under federal law, which regulates clinical laboratories that perform tests on human specimens and sets standards for facility administration, personnel qualifications and quality control. These standards apply to all settings, including commercial, hospital or physician office laboratories. (Code of Federal Regulations (CFR) Title 42 § 493)
- Defines CLIA waived tests as simple laboratory examinations and procedures that are approved by the Food and Drug Administration (FDA) for home use, employ methodologies that are simple and accurate as to render the likelihood of erroneous results negligible or pose no reasonable risk of harm to the patient if the test is performed incorrectly. (CFR Title 42 § 493)
This bill:
- Authorizes a person to perform an analysis of samples to test for SARS-CoV-2, the virus that causes COVID-19, in a clinical laboratory or a city, county, or city and county public health laboratory if they meet the requirements under CLIA for high complexity testing, as specified.
- Authorizes an entity contracted with and approved by the California Department of Public Health to operate a designated COVID-19 testing and dispensing site to acquire, dispense, and store COVID-19 oral therapeutics, as defined, at or from a designated site, until January 1, 2024.
- States that this bill is an urgency measure as the state of California emergency declaration, which went into effect in March of 2020, is set to sunset on February 28, 2023, upon the State of Emergency ending, active waivers that were issued under the authority of the State of Emergency and Executive Orders will also expire.
FISCAL EFFECT:
Unknown. This bill is keyed fiscal by Legislative Counsel.
COMMENTS:
- Purpose. The Author is the Sponsor of this bill. According to the Author, “The Governor’s formal announcement of the anticipated end date for the State of Emergency declaration stated that ‘to maintain California’s COVID-19 laboratory testing and therapeutics treatment capacity, the Newsom Administration will be seeking two statutory changes immediately upon the Legislature’s return: 1) The continued ability of nurses to dispense COVID-19 therapeutics; and 2) The continued ability of laboratory workers to solely process COVID-19 tests.’ This bill was introduced in response to that request.”
- Background.
Federal and State Regulation for Clinical Laboratory Testing. A facility that performs laboratory tests on human specimens for diagnosis or assessment must be certified under CLIA. CLIA certification requirements vary depending on the complexity of the laboratory tests performed.
Clinical laboratories or other testing sites need to know whether each test system used is waived, moderate, or high complexity. In general, the more complicated the test, the more stringent the requirements, including increased training and licensing of laboratory personnel. At a minimum, all laboratories must have a licensed clinical laboratory director. The FDA determines the complexity of CLIA laboratory tests. Waived tests are simple tests with a low risk for an incorrect result. They include tests listed in the CLIA regulations, tests cleared by the FDA for home use, and tests approved for waiver by the FDA using the CLIA criteria. Tests not classified as waived are assigned a moderate or high complexity category based on seven criteria given in the CLIA regulations, including ease of use, knowledge required, and types of materials tested. For commercially available FDA-cleared or approved tests, the test complexity is determined by the FDA during the pre-market approval process. While CLIA establishes minimum federal standards, it allows states to enact more stringent state law requirements.
Drug Dispensing. Current law prohibits a prescriber from dispensing drugs or dangerous devices to patients in the prescriber’s office or place of practice without specified conditions being met. These conditions include the following:
- The dangerous drugs or dangerous devices are dispensed to the prescriber’s own patient, and the drugs or dangerous devices are not furnished by a nurse or physician attendant.
- The dangerous drugs or dangerous devices are necessary in the treatment of the condition for which the prescriber is attending the patient.
- The prescriber does not keep a pharmacy, open shop, or drugstore, advertised or otherwise, for the retailing of dangerous drugs, dangerous devices, or poisons.
- The prescriber fulfills all of the labeling requirements imposed upon pharmacists, all of the specified recordkeeping requirements and all of the packaging requirements of good pharmaceutical practice, including the use of childproof containers.
- The prescriber does not use a dispensing device unless the prescriber personally owns the device and the contents of the device, and personally dispenses the dangerous drugs or dangerous devices to the patient packaged, labeled, and recorded, as specified.
- The prescriber, before dispensing, offers to give a written prescription to the patient that the patient may elect to have filled by the prescriber or by any pharmacy.
- The prescriber provides the patient with written disclosure that the patient has a choice between obtaining the prescription from the dispensing prescriber or obtaining the prescription at a pharmacy of the patient’s choice.
- A certified nurse-midwife who functions pursuant to a standardized procedure or protocol as specified, a nurse practitioner who functions pursuant to a standardized procedure as specified, or protocol, a physician assistant who functions as specified, or a naturopathic doctor who functions as specified, may hand to a patient of the supervising physician and surgeon a properly labeled prescription drug prepackaged by a physician and surgeon, a manufacturer as defined in this chapter, or a pharmacist.
“Prescriber” here refers to a person who holds a physician’s and surgeon’s certificate, a license to practice optometry, a license to practice naturopathic medicine, a license to practice dentistry, a license to practice veterinary medicine, a certificate to practice podiatry, or a certificate to practice as a nurse practitioner practicing, as specified, and who is duly registered by the Medical Board of California, the Osteopathic Medical Board of California, the California State Board of Optometry, the Bureau of Naturopathic Medicine, the Dental Board of California, the Veterinary Medical Board, the Podiatric Medical Board of California, or the Board of Registered Nursing.
Additional Authority In Response To the COVID-19 Pandemic. In the wake of the COVID-19 pandemic, federal and state governments expedited certain processes and waived certain requirements to protect the health and safety of the public. At the federal level, this meant providing emergency use authorizations for COVID-19 tests and vaccines.
In 2020, California undertook similar efforts to combat the COVID-19 pandemic. In March 2020, the Governor issued Executive Order N-25-20 (EO) to suspend statutes and regulations in support of the state’s pandemic response efforts. One part of the EO states:
“The certification and licensure requirements of California Code of Regulations, Title 17, section 1079 and Business and Professions Code section 1206.5 are suspended as to all persons who meet the requirements under the Clinical Laboratory Improvement Amendments of section 353 of the Public Health Service Act for high complexity testing and who are performing analysis of samples to test for SARS-CoV-2, the virus that causes COVID-19, in any certified public health laboratory or licensed clinical laboratory.”
Therefore, anyone who meets the CLIA requirements for high complexity testing can perform analyses of samples to test for SARS-CoV-2, the virus that causes COVID-19, in any certified public health laboratory or licensed clinical laboratory. Professionals who are able to perform these tests due to the waiver include a physician, podiatrist, dentist, naturopathic doctor, person licensed to engage in clinical laboratory practice or to direct a clinical lab, physician assistant, perfusionist, respiratory care practitioner, medical assistant, pharmacist, naturopathic assistant, licensed optometrist, other health care personnel providing direct patient care, any other person performing non-diagnostic testing, as specified. This expansion of professionals allowed for the increased staff required to support California through the COVID-19 pandemic.
Given that this EO’s authority relies on a Governor-issued state of emergency, and given that the Governor has stated that California’s COVID-19 state of emergency will end on February 28, 2023, the EO will no longer retain the force of law after this date.
Test to Treat Sites. As noted in the CDPH’s “Test-to-Treat” playbook, “test-to-treat as a concept generally applies to any efforts to ensure the key elements of (1) testing, (2) prescriber, and (3) medication occur expeditiously. This is particularly critical for COVID-19, as therapeutics must be given within 5-7 days of symptoms onset in order to be effective. With the advent of at-home antigen tests and
telehealth, expedited access may include streamlined steps that take place outside of a physical provider office or clinic site.”
CDPH currently approves OptumServe sites to offer antigen testing, telehealth prescribing for COVID-positive patients, and on-site Paxlovid and molnupiravir dispensing in one setting, as opposed to obtaining a prescription fill at an offsite traditional pharmacy.
BPC § 4062(b) authorizes, during a declared federal, state, or local emergency, the BOP to waive application of any provisions of the Pharmacy Law or BOP regulations if, in BOP’s opinion, the waiver will aid in the protection of public health or the provision of patient care. Per BPC § 4062(d), the BOP is permitted to extend any of its waivers issued under BPC § 4062(b), by 90 days after the end of a declared state of emergency.
Since a key aspect of the CDPH’s Test-to-Treat program involves dispensing therapeutics, the BOP waived Article 12 of Pharmacy Law which requires compliance with various requirements for storage and dispensing of drugs. Under its continued authority to issue waivers during a state of emergency, on April 19, 2022, the BOP issued a limited waiver applicable only to the CDPH, which waived specified statutory restrictions on entities operating a testing site approved by the CDPH to dispense COVID-19 oral therapeutics from state supplies, under the following specified conditions:
- The Approved Site complies with all conditions of the FDA approval or authorization of the COVID-19 Oral Therapeutic issued under an EUA, guidance of the federal Health and Human Services Agency and the FDA, and applicable federal dispensing laws.
- The Approved Site complies with all of the required conditions of any agreement or attestation required to be signed by organizations participating in the federal Program.
- The Approved Site also complies with all guidance and requirements established by CDPH.
The BOP’s waiver also required Test-to-Treat sites to comply with a series of additional requirements relating to drug container labeling, storage, and recordkeeping. The BOP’s waiver was set to expire at the end of 2022; the waiver was subsequently extended on December 5, 2022. In the Governor’s October 2022 press release declaring the end of the State’s COVID-19 State of Emergency effective, February 28, 2023, the Governor noted, “To maintain California’s COVID-19 laboratory testing and therapeutics treatment capacity, the Newsom Administration will be seeking two statutory changes immediately upon the Legislature’s return: 1) The continued ability of nurses to dispense COVID-19 therapeutics; and 2) The continued ability of laboratory workers to solely process COVID-19 tests,” which this bill seeks to do.
- Arguments in Support. The County Health Executives Association of California (CHEAC) supports this measure, noting that “California’s 28 public health laboratories play a critical role in COVID-19 testing for our communities. Further, COVID-19 therapeutics help to prevent or treat eligible non-hospital patients who have tested positive for COVID-19 and can improve outcomes, reduce stress on healthcare facilities, and even save lives. As we move beyond the state of emergency, it is important that California retain necessary tools to protect our communities from COVID-19.”
The California Association of Public Health Laboratory Directors (CAPHLD) writes in support: “[CAPHLD] is proud to support AB 269 which would extend the waiver for personnel conducting testing for SARs….We would like to suggest that the extension of the waiver from meeting state requirements be broadened to include additional outbreaks that may occur in this time period and beyond.”
The California Clinical Laboratory Association (CCLA) states that “The testing waiver specifically helps laboratories meet testing demands in the face of workforce shortages.”
Quest Diagnostics writes in support: “[Executive Order N-25-20] was critical to the state’s response to the COVID-19 pandemic and enabled the lab community to ensure enough resources were available to support testing demand….Further, there have been no adverse implications to test quality since the Executive Order….Quest Diagnostics relies on the Executive Order to continue to meet testing demands, especially in the face of a broader workforce shortage in the lab industry in California. Currently, 20 percent of Quest Diagnostics’ personnel that are conducting COVID-19 tests are doing so under the flexibility granted via the Executive Order. If the Executive Order were not codified into law and instead allowed to sunset, labs would be challenged to meet current and future COVID-19 testing demand as well as face exacerbated challenges performing other tests due to workforce shortages.”
- Arguments in Opposition. The California Association of Medical Laboratory Technology (CAMLT) notes that “The EO, though necessary at the outset of the pandemic, is no longer necessary or appropriate in California. Lowering testing personnel requirements from the long-standing CA standards has many negative consequences. Since March 2020, there have been numerous complaints at the local, state, and national levels against laboratories who employed unlicensed testing personnel to perform COVID-19 testing. Complaints include testing quality issues and less accurate results due to unlicensed personnel performing the tests. Since March 2020, clinical laboratories employing only licensed testing personnel which adhere to CA laboratory law have adapted, staffed up and now provide fully accessible, affordable, accurate, and timely COVID-19 testing services. There is absolutely no need to codify and extend a temporary waiver after the state of emergency ends on February 28, 2023.”
- Policy Consideration: Sunset Dates. Section 2 of this bill related to the dispensing of COVID-19 oral therapeutics will expire on January 1, 2024, likely because Test-to-Treat sites may no longer have the need to be operational by the end of the year. However, the provisions of this measure allowing a person to test for COVID-19 if they meet CLIA requirements in both clinical laboratory and city and county public health laboratory settings will extend beyond 2024 since they do not also include a sunset date. Given that it remains unclear whether the volume of testing for COVID-19 will remain the same over time as it has been for the past number of years during the State of Emergency, it may be appropriate for the authority provided in this measure to be reevaluated through the inclusion of a sunset date on all sections of the bill in order to allow for a thorough determination about the necessity of permanent authority to conduct these tests.
Entities Contracted With And Approved By The Department. While there is currently only one entity contracted with and approved by CDPH to provide services through the Test-to-Treat program, the drafting of this measure could potentially open the door for any contracted entities to operate without the protections outlined in the Pharmacy Law for drug acquisition, storage, and dispensing. It may be appropriate for this authority to be further narrowed to ensure additional entities beyond the unique settings providing important Test-to-Treat care defined in this bill are not potentially able to provide services outside of the traditional parameters outlined in Pharmacy Law.
SUPPORT AND OPPOSITION:
Support:
County Health Executives Association of California
Health Officers Association of California
The California Association of Public Health Laboratory Directors
The California Clinical Laboratory Association
The California Pan-Ethnic Health Network
Quest Diagnostics
Opposition:
The California Association of Medical Laboratory Technology
-- END --
ASSEMBLY THIRD READING
ATR Bill Id:AB 269
Author:(Berman)
As Amended Ver:February 8, 2023
2/3 vote. Urgency
SUMMARY
Codifies two waivers granted by the Governor during the declared COVID-19 State of Emergency through an urgency measure to take effect prior to that declaration’s anticipated termination on February 28, 2023.
Major Provisions
- Authorizes an entity approved by the California Department of Public Health (CDPH) to operate a designated COVID-19 testing and dispensing site to acquire, dispense, and store COVID-19 oral therapeutics at, or from, a designated site until January 1, 2024.
- Authorizes a person who meets the CLIA requirements for high complexity testing to perform an analysis of samples to test for SARS-CoV-2, the virus that causes COVID-19, in either a clinical laboratory or a city or county public health laboratory.
- Declares the act to be an urgency statute that will take effect immediately in order to ensure the continued ability of nurses to dispense COVID-19 therapeutics as part of the Test to Treat Program and address the technical qualifications of laboratory workers allowing them to solely process COVID-19 tests.
COMMENTS
Clinical Laboratory Testing Requirements. Federal and state laws regulate clinical laboratory testing on human specimens for diagnostic or assessment purposes. The purpose of clinical laboratory regulation is to ensure patients who undergo diagnostic testing receive accurate and timely results. Inaccurate or delayed results may prevent a patient from receiving the proper level or type of care.
To that end, all clinical laboratories and tests must comply with requirements under CLIA. CLIA establishes the minimum standards under federal law but allows states to establish more stringent requirements. Under CLIA, laboratory tests are classified based on the complexity of the laboratory tests performed. In general, the more complicated the test, the stricter the requirements relating to the test, including the requirements for training and licensing of the laboratory personnel performing the test.
The federal FDA is the entity that determines the complexity of laboratory tests. Waived tests are simple tests with a low risk of incorrect results. They include tests listed in the CLIA regulations, tests cleared by the FDA for home use (such as pregnancy tests), and tests approved for a waiver by the FDA using the CLIA criteria. Tests not classified as waived are assigned a moderate or high complexity category based on seven criteria given in the CLIA regulations, including ease of use, the knowledge required, and types of materials tested. For commercially available FDA-cleared or approved tests, the test complexity is determined by the FDA during the pre-market approval process.
Under both federal and California law, any healthcare personnel providing direct patient care or any person as part of a nondiagnostic health assessment program may perform a waived test in a licensed laboratory. Various licensed professionals and scientists are enumerated through Section 1206.5 of the Business and Professions Code, with additional supervision requirements and testing scope limitations specified for certain licensees. High complexity testing requires more advanced licensure than moderate or waived tests. Generally speaking, California law is more restrictive than the federal requirements in terms of who may perform testing.
There are two types of tests used to detect SARS-CoV-2, the virus that causes COVID-19. The first type is diagnostic tests, which will reveal if an individual has an active coronavirus infection. Diagnostic tests include both antigen tests (which detect the presence of certain viral proteins) and molecular tests (which detect viral genetic material). The second type of COVID-19 test is antibody tests, which use a blood sample to detect antibodies that could reveal either an active or a previous infection. Tests for SARS-CoV-2 have been deemed CLIA-waived for the duration of the federal emergency declaration through the FDA's Emergency Use Authorization.
Emergency Waivers for COVID-19 Testing. Executive Order N-25-20, issued just days into the declared emergency on March 12, 2020, waived various statutes and regulations that were found to obstruct the state’s nascent pandemic response efforts. Paragraph nine of the Order consisted of the following provision:
"The certification and licensure requirements of California Code of Regulations, Title 17, section 1079 and Business and Professions Code section 1206.5 are suspended as to all persons who meet the requirements under the Clinical Laboratory Improvement Amendments of section 353 of the Public Health Service Act for high complexity testing and who are performing analysis of samples to test for SARS-CoV-2, the virus that causes COVID-19, in any certified public health laboratory or licensed clinical laboratory."
This executive order substantially broadened the available workforce for individuals to perform analysis of COVID-19 tests. Because California requirements are considered more restrictive than the federal regulations, laboratories utilizing the waiver have been able to utilize professionals who meet federal standards but who would not currently qualify under Section 1206.5. This increased capacity has been essential to California's robust response to the COVID-19 pandemic through the proliferation of testing options.
Because Executive Order N-25-20's authority relied on the active State of Emergency declared by the Governor, it will no longer have the force of law immediately upon the expiration of that declaration. The Governor has stated that the declaration will be terminated on February 28, 2023. However, the formal end of the declared emergency will not mean an end to the need for widely available COVID-19 testing. In his announcement regarding his timeline, the Governor requested statutory changes to ensure "the continued ability of laboratory workers to solely process COVID-19 tests." This bill would effectuate that request by continuing to waive state requirements for individuals analyzing COVID-19 tests who meet the federal requirements for high complexity testing.
COVID-19 Therapeutics. The FDA has authorized two oral antiviral pills for the treatment of mild-to-moderate COVID-19. Paxlovid, developed by Pfizer, is a combination formulation of two protease inhibitor medications: nirmatrelvir and ritonavirhas. Molnupiravir, developed by Merck & Co., is sold under the brand name Lagevrio. Both therapeutics have been shown to prevent hospitalization or death in high-risk patients with mild to moderate COVID-19.
As antiviral therapeutics for COVID-19 became available at the beginning of 2022, the CDPH and other public health entities have pushed to make those treatments accessible, particularly to high-risk patients. Therapeutics have been made free to all Californians, including the uninsured. COVID-19 therapeutics are most effective when taken within days of a patient developing symptoms, so beginning treatment immediately upon receipt of a positive test is the most efficacious way of prevent a patient’s condition from becoming more severe.
Despite the effectiveness and wide availability of COVID-19 therapeutics, it was reported in 2022 that the antiviral medications were being underutilized, particularly within low-income communities and communities of color. The CDPH issued a health advisory for California healthcare providers urging a low threshold to prescribe COVID-19 therapeutics. The Governor repeatedly stated that his objective was to "remedy ongoing inequities in therapeutics access."
In May 2022, the CDPH announced that it was upgrading 146 existing testing sites to "Test to Treat" locations where individuals could be seen by a provider and receive a prescription for oral antiviral therapeutics immediately upon testing positive for COVID-19. This initiative was launched as a partnership with OptumServe, a company with existing contracts with the state to provide vaccination and testing site services. The state’s program aligned with the Biden Administration’s national Test to Treat initiative in the National COVID-19 Preparedness Plan.
Test to Treat sites are located in areas where access to insurance and health services is considered lower. Clinics traditionally serving these populations have not historically had the operational workflows required to coordinate access to therapeutics as part of their testing programs. The OptumServe sites offer antigen testing, telehealth prescribing for COVID-positive patients, and on-site Paxlovid and molnupiravir dispensing.
Pharmacy Waivers. In addition to the Governor’s emergency powers under EMSA, the California State Board of Pharmacy (BOP) has its own statutory authority to waive provisions of the Pharmacy Law and its implementing regulations. California law provides that "during a declared federal, state, or local emergency, the board may waive application of any provisions of this chapter or the regulations adopted pursuant to it if, in the board's opinion, the waiver will aid in the protection of public health or the provision of patient care." This allowed the BOP to quickly waive laws that would have hindered the state's pandemic response independent of either EMSA or the waiver process established through the Governor’s executive order.
Because a key aspect of the CDPH's Test to Treat program involves the dispensation of COVID-19 therapeutics, the BOP waived provisions of the Pharmacy Law that would have prohibited those drugs from being stored and dispensed outside of a clinical setting or pharmacy. On April 19, 2022, the BOP issued a limited waiver to the CDPH waiving any statutory restrictions on entities operating a testing site approved by the CDPH to dispense COVID-19 oral therapeutics from state supplies, under specified conditions.
The BOP's waiver also required Test to Treat sites to comply with a series of additional requirements relating to drug container labeling, storage, and recordkeeping. The original waiver was scheduled to expire at the end of 2022; the waiver was subsequently extended on December 5, 2022. However, because the BOP’s waiver authority remains dependent on an actively declared state of emergency, the authority granted by the board to the CDPH is currently set to expire on February 28, 2023 when the State of Emergency is terminated.
The expiry of the BOP’s waiver would mean that patients who receive positive COVID-19 tests at a Test to Treat site would have to be directed to pick up their therapeutics at a nearby pharmacy or through a mail order, which could delay treatment and exacerbate inequities. In light of this, the Governor called in his press release announcing the end of the COVID-19 State of Emergency for statutory changes to preserve "the continued ability of nurses to dispense COVID-19 therapeutics" at Test to Treat sites.
This bill would codify the BOP waiver for purposes of allowing COVID-19 therapeutics such as Paxlovid and molnupiravir to be stored and dispensed at Test to Treat locations. The bill would place into statute the same patient safety requirements as the BOP's waiver. The provision of the bill related to COVID-19 therapeutic dispending would also be subjected to repeal on January 1, 2024, allowing for the Test to Treat program to continue operating under their existing model through the end of the year.
According to the Author
"The Governor’s press release announcing an anticipated February 28, 2023 termination date for the declared COVID-19 State of Emergency included the following: 'To maintain California's COVID-19 laboratory testing and therapeutics treatment capacity, the Newsom Administration will be seeking two statutory changes immediately upon the Legislature's return: 1) The continued ability of nurses to dispense COVID-19 therapeutics; and 2) The continued ability of laboratory workers to solely process COVID-19 tests.' This bill would fulfill the Governor's request by codifying both of the existing waivers identified in this press release."
Arguments in Support
Quest Diagnostics supports this bill, writing that the Governor's executive order relating to clinical laboratory requirements "was critical to the state's response to the COVID-19 pandemic and enabled the lab community to ensure enough resources were available to support testing demand. Without the flexibility granted by the Executive Order, COVID-19 testing demand would have surpassed lab resources, potentially leaving Californians without timely results to COVID-19 tests which have been key to managing the spread of the virus. Further, there have been no adverse implications to test quality since the Executive Order."
Arguments in Opposition
None on file.
FISCAL COMMENTS
Unknown.
VOTES
ASM BUSINESS AND PROFESSIONS: 17-0-2
YES: Berman, Flora, Alvarez, Bains, Bonta, Essayli, Dixon, Gipson, Grayson, Irwin, Jackson, Lee, Lowenthal, McCarty, McKinnor, Stephanie Nguyen, Ting
ABS, ABST OR NV: Alanis, Joe Patterson
ASM HEALTH: 11-0-4
YES: Wood, Waldron, Aguiar-Curry, Arambula, Boerner Horvath, Wendy Carrillo, Vince Fong, Maienschein, Joe Patterson, Rodriguez, Weber
ABS, ABST OR NV: Flora, McCarty, Santiago, Villapudua
UPDATED
VERSION: February 8, 2023
CONSULTANT: Robert Sumner / B. & P. / (916) 319-3301 FN: 0000008
Date of Hearing: February 15, 2023
ASSEMBLY COMMITTEE ON HEALTH
Jim Wood, Chair
ABPCA Bill Id:AB 269
Author:(Berman) – As Amended Ver:February 8, 2023
SUBJECT: Public health: COVID-19 testing and dispensing sites.
SUMMARY: Permits a person to perform an analysis of samples to test for SARS-CoV-2, the virus that causes COVID-19, in a 1) clinical laboratory or, 2) in any city or county public health laboratory if they met federal regulatory requirements under the Clinical Laboratory Improvement Amendments (CLIA), as specified, for high complexity testing. Permits an entity contracted with and approved by the Department of Public Health (DPH) to operate a designated COVID-19 testing and dispensing site to acquire, dispense, and store COVID-19 therapeutics at or from a designated site. Includes provisions relating to the dispensing, labeling, and recording of COVID-19 therapeutics. Contains an urgency clause to ensure that the provisions of this bill go into immediate effect upon enactment. Specifically, this bill:
- Permits a person to perform an analysis of samples to test for SARS-CoV-2, the virus that causes COVID-19, in: a) clinical laboratory or, b) in any city or county public health laboratory if they meet certain federal CLIA requirements for high complexity testing, as specified. (See discussion in background.)
- Permits an entity contracted with and approved by DPH to operate a designated COVID-19 testing and dispensing site to acquire, dispense, and store COVID-19 therapeutics at or from a designated site. Requires COVID-19 oral therapeutics to be stored in a secure manner, as determined by DPH.
- Authorizes a prescribing physician, or a registered nurse under the direction of such physician, to dispense COVID-19 oral therapeutics to patients at a designated site.
- Requires COVID-19 oral therapeutics that are packaged by the manufacturer in a dispensable container to be dispensed in the original manufacturer’s container. Requires each COVID-19 oral therapeutic to be labeled, as follows: name/manufacturer of the drug, direction for use, name of patient, prescriber name, date of issue, strength of the drug, quantity of drug, and expiration date. Requires the label to include the address of the designated site where the therapeutic is dispensed.
- Requires an entity contracted with and approved by DPH to operate a designated site pursuant to 2) above to maintain for three years records of acquisition and disposition for each site, including the kind and amounts of COVID-19 oral therapeutics dispensed at each site and for each patient. Requires the records to be available for inspection by DPH and the Board of Pharmacy (BOP).
- Defines COVID-19 oral therapeutics to mean drugs that are approved or authorized by the United States Food and Drug Administration (FDA) for the treatment of COVID-19 and administered orally.
- Specifies that 2) through 6) above to remain in effect only until January 1, 2024, as specified.
EXISTING LAW:
- Establishes CLIA under federal law which specifies requirements for all laboratories to perform testing on human specimens. [42 U.S.C Section 263a; P.L. 100-578 Title 42, Part 493 et.seq CFR]
- Provides for the licensure, registration, and regulation of clinical laboratories and various clinical laboratory personnel by DPH with specified exceptions. [Business and Professions Code (BPC) § 1200-1327].
- Defines “clinical laboratory” as any place used, or any establishment or institution organized or operated, for the performance of clinical laboratory tests or examinations or the practical application of the clinical laboratory sciences. That application may include any means that applies the clinical laboratory sciences. [BPC § 1206(a)(8)]
- Defines “clinical laboratory test or examination” as the detection, identification, measurement, evaluation, correlation, monitoring, and reporting of any particular analyte, entity, or substance within a biological specimen for the purpose of obtaining scientific data which may be used as an aid to ascertain the presence, progress, and source of a disease or physiological condition in a human being, or used as an aid in the prevention, prognosis, monitoring, or treatment of a physiological or pathological condition in a human being, or for the performance of nondiagnostic tests for assessing the health of an individual. [BPC § 1206(a)(5)]
- Prohibits any person from performing clinical laboratory tests or examinations classified as of high complexity under CLIA unless the clinical laboratory test or examination is performed under the overall operation and administration of the laboratory director and the test is performed by specified licensees or individuals. [BPC § 1206.5(c)]
- Permits a clinical laboratory bioanalyst or bioanalyst and qualified under CLIA, who is not the CLIA laboratory director to perform clinical laboratory tests or examinations classified as of high complexity under CLIA, as specified. [BPC §1203]
- Requires a local health department of a city or county to make available the services of a public health laboratory for the examination of specimens from suspected cases of infectious and environmental disease, as specified. Requires the public health laboratory to also provide the analyses required to assist in community disease surveillance and to meet the responsibilities and support the programs of the local health department. [Health and Safety Code (HSC) §101150]
- Requires the city or county public health laboratory and its personnel to be approved by DPH and to comply with the requirements of CLIA. [HSC § 101160]
- Establishes the BOP to administer the Pharmacy Law. Specifies labeling, recording and storage requirements for dangerous drugs and devices. [BPC §4000 et seq.]
- Defines “dispense” to include the furnishing of drugs or devices directly to a patient by a physician, nurse practitioner, dentist, optometrist, podiatrist, or veterinarian, or other health professional when acting within the scope of their practice. [BPC §4024 (b)]
- Prohibits a prescriber from dispensing drugs or dangerous devices to patients in the prescriber’s office or place of practice unless specified conditions are met. [BPC § 4170]
- Authorizes a registered nurse to dispense drugs or devices upon an order by a licensed physician and surgeon or other specified health professional if the registered nurse is functioning within a licensed primary care clinic. [BPC § 2725.1]
- Authorizes the Governor, under the California Emergency Services Act, to proclaim a state of emergency when specified conditions of disaster or extreme peril to the safety of persons and property exist. Confers on the Governor specified emergency powers, including making amending and rescinding orders and regulations, as specified. Indicates that whenever the state of war emergency or state of emergency has been terminated, the orders and regulations shall be of no further force or effect. [Government Code §8550 et seq.]
FISCAL EFFECT: Unknown. This bill has not been analyzed by a fiscal committee.
COMMENTS:
- PURPOSE OF THIS BILL. According to the author, the Governor’s press release announcing an anticipated February 28, 2023 termination date for the declared COVID-19 State of Emergency included the following statement: “To maintain California’s COVID-19 laboratory testing and therapeutics treatment capacity, the Newsom Administration will be seeking two statutory changes immediately upon the Legislature’s return: a) the continued ability of nurses to dispense COVID-19 therapeutics; and, b) the continued ability of laboratory workers to solely process COVID-19 tests.” The author concludes this bill would fulfill the Governor’s request by codifying existing waivers.
- BACKGROUND. COVID-19 is a viral respiratory illness caused by a new coronavirus. Coronaviruses are a large family of viruses that are common in people and many different species of animals, including camels, cattle, cats, and bats. COVID-19 was first reported in Wuhan, Hubei Province, China in November 2019. COVID-19 was declared a pandemic by the World Health Organization on March 11, 2020. COVID-19 can cause mild to severe illness; most severe illness occurs in adults 65 years and older and people of any age with serious underlying medical problems. Due to the severity of the COVID-19 crisis, on March 4, 2020, Governor Newsom issued an Executive Order declaring a state of emergency and on March 19, 2020, issued a stay at home order.
- CLIA WAIVER. On March 12, 2020 Governor Newsom signed Executive Order N-25-20, to among various orders, suspend the certification and licensure requirements for persons who perform a clinical laboratory test or examination classified as high complexity under CLIA and who are performing analysis of samples to test for SARS-CoV-2, the virus that causes COVID-19, in any certified public health laboratory or licensed clinical laboratory. This Executive Order broadened the available workforce who can perform analysis of COVID-19 tests. Since California requirements are considered more restrictive than federal regulations, laboratories utilizing the waiver were able to use professionals who meet federal CLIA standards but who would not qualify under California law as described in c) i) below. This Executive Order substantially broadened the available workforce for individuals to perform analysis of COVID-19 tests. On October 17, 2022, Governor Gavin Newsom announced that the COVID-19 State of Emergency will end on February 28, 2023, thus all the waivers associated with the State of Emergency will also expire.
- Types of Tests. There are two types of COVID-19 tests:
- Molecular tests, such as polymerase chain reaction (PCR) tests detect genetic material from the virus and can help diagnose an active COVID-19 infection. PCR tests can be highly accurate but running the tests and analyzing the results can take minutes. Most molecular tests authorized under Emergency Use Authorization (EUAs) are classified as moderate and high complexity tests, but several are waived tests (as discussed below). Antigen tests, often referred to as rapid tests or, for some, at-home or self-tests, which detect proteins called antigens from the virus are less sensitive as molecular PCR tests.
- Serological (Antibody) Tests look for antibodies to the SARS-CoV-2 virus, which can help identify individuals who have developed an adaptive immune response to the virus, as part of an either active infection or a prior infection. Serological, or antibody tests should not be used to diagnose active infection. The FDA has issued several EUA for serological tests but these tests must be performed in clinical laboratories.
- CLINICAL LABORATORY TESTING REQUIREMENTS. Federal and state laws regulate clinical laboratory testing on human specimens for diagnostic or assessment purposes. These requirements help ensure reliable, accurate and timely results. As such, all clinical laboratories and tests must comply with the requirements of CLIA which establishes minimum standards but states are allowed to adopt more stringent requirements. CLIA classifies tests based on the complexity of the laboratory tests performed. The more complicated the tests, the stricter the requirements, including requirements for training and licensing of the laboratory personnel performing the test. The FDA is the entity that determines the complexity of laboratory tests.
Waived tests are simple tests with a low risk of incorrect results. They include tests listed in the CLIA regulations, tests cleared by the FDA for home use (such as pregnancy tests), and tests approved for a waiver by the FDA using the CLIA criteria. Tests not classified as waived are assigned a moderate or high complexity category based on seven criteria given in the CLIA regulations, including ease of use, the knowledge required, and types of materials tested. For commercially available FDA-cleared or approved tests, the test complexity is determined by the FDA during the pre-market approval process. Under both federal and California law, any healthcare personnel providing direct patient care or any person as part of a nondiagnostic health assessment program may perform a waived test in a licensed laboratory. Various licensed professionals and scientists are enumerated through BPC §1206.5, with additional supervision requirements and testing scope limitations specified for certain licensees. High complexity testing requires more advanced licensure than moderate or waived tests. Generally speaking, California’s requirements are more restrictive than federal law in terms of who may perform testing.
This bill authorizes a person to perform an analysis of samples to test for COVID-19 virus in a clinical laboratory or a city, county, or city and county public health laboratory if they meet the federal requirements under CLIA for high complexity testing and not meeting state requirements.- State Requirements for High Complexity Testing. California law (BPC § 1206.5 (c)) requires that a person who performs clinical laboratory tests or examinations classified as of high complexity must perform the test or examinations under the overall operation and administration of the laboratory director, and the test is performed by any of the following persons:
- A licensed physician and surgeon holding a Medical Doctor (M.D.) or Doctor of Osteopathy (D.O.) degree;
- A licensed podiatrist or a licensed dentist, as specified;
- A person licensed to engage in clinical laboratory practice or to direct a clinical laboratory test if the test or examination is within a specialty or subspecialty authorized by the person’s certification;
- A licensed physician assistant, as specified;
- A perfusionist, as specified;
- A respiratory care practitioner, as specified;
- A person performing nuclear medicine technology, as specified;
- Any person if performing blood gas analysis, as specified; and,
- Any other person within a physician office laboratory if the test is performed under the onsite supervision of the patient’s physician and surgeon or podiatrist who shall: (A) ensure that the person is performing test methods as required for accurate and reliable tests; and, (B) have personal knowledge of the results of clinical laboratory testing or examination performed by that person before the test results are reported from the laboratory.
- Federal CLIA Requirements for High Complexity Testing. Federal regulations (Section 493.1489 of Title 42 of the Code of Federal Regulations) require that to perform high complexity testing, an individual must possess a current license issued by the state in which the laboratory is located, if such licensing is required, and meet one of the following requirements:
- Be a licensed M.D. D.O, or doctor of podiatric medicine in the state in which the laboratory is located or have earned a doctoral, master’s or bachelor’s degree in a chemical, physical, biological, or clinical laboratory science, or medical technology from an accredited institution;
- Either:
- Have earned an associate degree in a laboratory science, or medical technology from an accredited institution; or,
- Have education or training equivalent to (ii) (1) above, as specified;
- Have previously qualified or could have qualified as a technologist, as specified, on or before February 28, 1992;
- On or before April 24, 1995, be a high school graduate or equivalent and have either graduated from a specified training program or completed an official U.S. military medical laboratory procedures training course, as specified;
- Until September 1, 1997, have earned a high school diploma or equivalent; and have documentation of training appropriate for the testing performed before analyzing patient specimens, as specified; or,
- As of September 1, 1997, be qualified under (1), (ii) or (iv) above, except for those individuals qualified under (v) (1) who were performing high complexity testing on or before April 24, 1995.
- State Requirements for High Complexity Testing. California law (BPC § 1206.5 (c)) requires that a person who performs clinical laboratory tests or examinations classified as of high complexity must perform the test or examinations under the overall operation and administration of the laboratory director, and the test is performed by any of the following persons:
- COVID-19 Therapies. Although this bill only applies to oral therapeutics, it should be noted that there are currently five outpatient drugs with FDA approval/EUA for COVID-19. One, tixagevimab/cilgavimab, is a pre-exposure prophylactic drug prescribed for persons who are immunocompromised and are not likely to respond to vaccination or cannot be immunized to decrease the likelihood of infection. An injectable drug generally administered by a clinician, it is generally covered under a medical benefit. The other four are treatment drugs prescribed to persons for whom post-infection hospitalization seems likely in order to decrease hospitalization likelihood. Two, remdesivir and bebtelovimab, are injected or infused drugs, generally administered by a clinician and generally covered under a medical benefit. The other two, nirmatrelvir/ritonavir (Paxlovid) and molnupiravir, are oral drugs generally available through a pharmacy and generally covered under a pharmacy benefit. The standard treatment path calls for one of the four treatment drugs to be chosen and use begun within five to seven days of symptom onset.
- DOUBLE REFFERAL. This bill is double referred and is scheduled to be heard in the Assembly Business and Professions Committee on Tuesday, February 14, 2023.
- SUPPORT. Supporters, such as the California Clinical Lab Association and Quest Diagnostics, claim this bill is necessary in the continued fight against COVID-19, and the testing waiver specifically helps laboratories meet testing demands in the face of workforce shortages.
The California Association of Public Health Laboratory Directors supports this bill but would like this bill to be broadened to include additional outbreaks that may occur. - OPPOSITION. The California Association for Medical Laboratory Technology (CAMLT) opposes this bill and states that lowering testing personnel requirements from the long-standing California standards has many negative consequences. Since March 2020, there have been numerous complaints at the local, state, and national levels against laboratories who employed unlicensed testing personnel to perform COVID-19 testing. Complaints include testing quality issues and less accurate results due to unlicensed personnel performing the tests. Since March 2020, clinical laboratories employing only licensed testing personnel which adhere to California laboratory law have adapted, staffed up and now provide fully accessible, affordable, accurate, and timely COVID-19 testing services. CAMLT concludes that there is absolutely no need to codify and extend a temporary waiver after the state of emergency ends on February 28, 2023.
- PREVIOUS LEGISLATION.
- SB 1423 (Pan), Chapter 545, Statutes of 2022, requires health plans and insurers to cover therapeutics for COVID-19, as specified, as well as makes other revisions to coverage requirements for COVID-19 testing and vaccination, and makes the annual open enrollment periods for individual health benefit plans offered through and outside of Covered California consistent.
- SB 510 (Pan), Chapter 729, Statutes of 2021, requires health plans and insurers to cover the costs associated with COVID-19 testing, immunization, and health care services related to testing with no cost-sharing or prior authorization or other utilization management during and following the federal public health emergency.
- COMMENT. This bill proposes to loosen state requirements for personnel conducting an analysis of COVID-19 tests if they meet federal CLIA requirements (see c) (ii) in Background) for high complexity tests. Federal CLIA requirements require a person to have a current license issued by the state in which the laboratory is located but only if such licensing is required by the state. Since this bill proposes to exclude the application of state licensing law, consistent with federal CLIA requirements, then the personnel conducting analysis of COVID-19 tests would be exempt from state licensure.
REGISTERED SUPPORT / OPPOSITION:
Support
California Association of Public Health Laboratory Directors
California Clinical Lab Association
Quest Diagnostics
Opposition
California Association for Medical Laboratory Technology
Analysis Prepared by: Rosielyn Pulmano / HEALTH / (916) 319-2097
Date of Hearing: February 14, 2023
ASSEMBLY COMMITTEE ON BUSINESS AND PROFESSIONS
Marc Berman, Chair
ABPCA Bill Id:AB 269
Author:(Berman) – As Amended Ver:February 8, 2023
SUBJECT: Public health: COVID-19 testing and dispensing sites.
SUMMARY: Codifies two waivers granted by the Governor during the declared COVID-19 State of Emergency through an urgency measure to take effect prior to that declaration’s anticipated termination on February 28, 2023.
EXISTING LAW:
- Establishes the Board of Pharmacy (BOP) to administer and regulate the Pharmacy Law. (Business and Professions Code (BPC) §§ 4000 et seq.)
- Defines “pharmacy” as an area, place, or premises licensed by the BOP in which the profession of pharmacy is practiced and where prescriptions are compounded. (BPC § 4037)
- Prohibits any person from conducting a pharmacy in the state unless they have obtained a license from the BOP. (BPC § 4110)
- Defines “dispense” to include the furnishing of drugs or devices directly to a patient by a physician, nurse practitioner, dentist, optometrist, podiatrist, or veterinarian, or other health professional when acting within the scope of their practice. (BPC § 4024(b))
- Requires labeling of all containers of prescription drugs stating information about the drug, directions for use, the names of the patient and the prescriber, and other information. (BPC § 4076)
- Requires that all records or other documentation of the acquisition and disposition of dangerous drugs and dangerous devices by any entity licensed by the BOP shall be retained on the licensed premises in a readily retrievable form for a period of three years. (BPC § 4105)
- Prohibits a prescriber from dispensing drugs or dangerous devices to patients in the prescriber’s office or place of practice unless specified conditions are met. (BPC § 4170)
- Requires a prescriber who dispenses drugs to store all drugs to be dispensed in an area that is secure. (BPC § 4172)
- Authorizes a registered nurse to dispense drugs or devices upon an order by a licensed physician and surgeon or other specified health professional if the registered nurse is functioning within a licensed primary care clinic. (BPC § 2725.1)
- During a declared federal, state, or local emergency, authorizes the BOP to waive application of any provisions of the Pharmacy Law or the regulations adopted pursuant to it if, in the BOP’s opinion, the waiver will aid in the protection of public health or the provision of patient care. (BPC § 4062)
- Provides for the licensure, registration, and regulation of clinical laboratories and various clinical laboratory personnel by the California Department of Public Health (CDPH), with specified exceptions. (BPC §§ 1200 – 1327)
- Defines “CLIA” as the federal Clinical Laboratory Improvement Amendments of 1988 (United States Code, title 42, § 263a; Public Law 100-578) and the regulations adopted by the federal Health Care Financing Administration (HFCA) that are effective on January 1, 1994, or later when adopted by the CDPH after being deemed equivalent to or more stringent than California laws or regulations, as specified. (BPC §§ 1202.5(a), 1208(b))
- Defines “clinical laboratory” as any place used, or any establishment or institution organized or operated, for the performance of clinical laboratory tests or examinations or the practical application of the clinical laboratory sciences. (BPC § 1206(a)(8))
- Defines “clinical laboratory test or examination” as the detection, identification, measurement, evaluation, correlation, monitoring, and reporting of any particular analyte, entity, or substance within a biological specimen for the purpose of obtaining scientific data which may be used as an aid to ascertain the presence, progress, and source of a disease or physiological condition in a human being, or used as an aid in the prevention, prognosis, monitoring, or treatment of a physiological or pathological condition in a human being, or for the performance of nondiagnostic tests for assessing the health of an individual. (BPC § 1206(a)(5))
- Prohibits any person from performing clinical laboratory tests or examinations classified as of high complexity under CLIA unless the clinical laboratory test or examination is performed under the overall operation and administration of the laboratory director and the test is performed by specified licensees or individuals enumerated in statute. (BPC § 1206.5)
- Establishes the definition, duties, and qualifications of a “laboratory director” for purposes of clinical laboratories and testing. (BPC § 1209)
- Includes in each specialized limited clinical laboratory scientist license specified specialties and subspecialties. (BPC § 1210)
- Requires the local health department of a city or county to have available the services of a public health laboratory for the examination of specimens from suspected cases of infectious and environmental diseases. (Health and Safety Code (HSC) § 101150)
- Provides that city or county public health laboratory and its personnel shall be approved by the State Department of Health Services (now the CDPH) and shall comply with the requirements of CLIA. (HSC § 101160)
- Establishes the California Emergency Services Act to confer upon the Governor and upon the chief executives and governing bodies of political subdivisions of the state certain emergency powers. (Government Code (GOV) §§ 8550 et seq.)
- Authorizes the Governor to make, amend, and rescind orders and regulations necessary to carry out the provisions of the California Emergency Services Act, which have the force and effect of law. (GOV § 8567)
THIS BILL:
- Defines “COVID-19 oral therapeutics” as drugs that are approved or authorized by the United States Food and Drug Administration (FDA) for the treatment of COVID-19 and administered orally.
- Authorizes an entity approved by the CDPH to operate a designated COVID-19 testing and dispensing site to acquire, dispense, and store COVID-19 oral therapeutics at or from a designated site.
- Requires COVID-19 oral therapeutics to be stored at a designated site in a secure manner, as determined by the CDPH.
- Expressly provides that a prescribing physician, or a registered nurse under the direction of such physician, may dispense COVID-19 oral therapeutics to patients at a designated site.
- Requires COVID-19 oral therapeutics that are packaged by the manufacturer in a dispensable container to be dispensed in the original manufacturer’s container and to comply with specified labeling requirements, including the address of the designated site where the therapeutic is dispensed.
- Requires an entity approved to operate a designated site to maintain for three years records of acquisition and disposition for each site, including the kind and amounts of COVID-19 oral therapeutics dispensed at each site and for each patient, and requires those records shall be available for inspection by the CDPH and the BOP.
- Provides that the above provisions shall remain in effect only until January 1, 2024.
- Authorizes a person who meets the CLIA requirements for high complexity testing to perform an analysis of samples to test for SARS-CoV-2, the virus that causes COVID-19, in either a clinical laboratory or a city or county public health laboratory.
- Declares the act to be an urgency statute that will take effect immediately in order to ensure the continued ability of nurses to dispense COVID-19 therapeutics as part of the Test to Treat Program and address the technical qualifications of laboratory workers allowing them to solely process COVID-19 tests.
FISCAL EFFECT: Unknown.
COMMENTS:
Purpose. This bill is sponsored by the author, who is the Chair of the Assembly Committee on Business and Professions. The Governor’s press release announcing an anticipated February 28, 2023 termination date for the declared COVID-19 State of Emergency included the following: “To maintain California’s COVID-19 laboratory testing and therapeutics treatment capacity, the Newsom Administration will be seeking two statutory changes immediately upon the Legislature’s return: 1) The continued ability of nurses to dispense COVID-19 therapeutics; and 2) The continued ability of laboratory workers to solely process COVID-19 tests.” This bill would fulfill the Governor’s request by codifying both of the existing waivers identified in this press release.
Background.
COVID-19 Pandemic. On March 4, 2020, Governor Gavin Newsom proclaimed a State of Emergency as a result of the impacts of the COVID-19 public health crisis. On March 12, 2020, the Governor issued an executive order that directed residents to follow public health directives and guidance, including to cancel large non-essential gatherings that do not meet certain state criteria. On March 19, 2020, the Governor formally issued a statewide “stay at home order,” directing Californians to only leave the house to provide or obtain specified essential services. Subsequent guidance from the State Public Health Officer expressly exempted from that order various professionals regulated by the Department of Consumer Affairs (DCA).
On March 30, 2020, Governor Newsom announced an initiative to “expand California’s health care workforce and recruit health care professionals to address the COVID-19 surge” and signed Executive Order N-39-20. This executive order established a waiver request process under the DCA and included other provisions authorizing the waiver of licensing, certification, and credentialing requirements for health care providers. This waiver process constituted a delegation of the Governor’s existing authority under the California Emergency Services Act (EMSA) to make, amend, and rescind orders and regulations necessary to respond to a declared emergency.
Approximately 74 further executive orders were issued to waive or revise various laws to advance the state’s pandemic response. Over the course of the pandemic, approximately 596 EO provisions were effectuated, with 27 still in effect as of October 2022. Dozens of additional waivers have been issued for licensing programs under the DCA. The majority of these waivers have since expired, and a number were permanently codified through the enactment of legislation.
Clinical Laboratory Testing Requirements. Federal and state laws regulate clinical laboratory testing on human specimens for diagnostic or assessment purposes. The purpose of clinical laboratory regulation is to ensure patients who undergo diagnostic testing receive accurate and timely results. Inaccurate or delayed results may prevent a patient from receiving the proper level or type of care.
To that end, all clinical laboratories and tests must comply with requirements under CLIA. CLIA establishes the minimum standards under federal law but allows states to establish more stringent requirements. Under CLIA, laboratory tests are classified based on the complexity of the laboratory tests performed. In general, the more complicated the test, the stricter the requirements relating to the test, including the requirements for training and licensing of the laboratory personnel performing the test.
The federal FDA is the entity that determines the complexity of laboratory tests. Waived tests are simple tests with a low risk of incorrect results. They include tests listed in the CLIA regulations, tests cleared by the FDA for home use (such as pregnancy tests), and tests approved for a waiver by the FDA using the CLIA criteria. Tests not classified as waived are assigned a moderate or high complexity category based on seven criteria given in the CLIA regulations, including ease of use, the knowledge required, and types of materials tested. For commercially available FDA-cleared or approved tests, the test complexity is determined by the FDA during the pre-market approval process.
Under both federal and California law, any healthcare personnel providing direct patient care or any person as part of a nondiagnostic health assessment program may perform a waived test in a licensed laboratory. Various licensed professionals and scientists are enumerated through Section 1206.5 of the Business and Professions Code, with additional supervision requirements and testing scope limitations specified for certain licensees. High complexity testing requires more advanced licensure than moderate or waived tests. Generally speaking, California law is more restrictive than the federal requirements in terms of who may perform testing.
There are two types of tests used to detect SARS-CoV-2, the virus that causes COVID-19. The first type is diagnostic tests, which will reveal if an individual has an active coronavirus infection; diagnostic tests include both antigen tests (which detect the presence of certain viral proteins) and molecular tests (which detect viral genetic material). The second type of COVID-19 test is antibody tests, which use a blood sample to detect antibodies that could reveal either an active or a previous infection. Tests for SARS-CoV-2 have been deemed CLIA-waived for the duration of the federal emergency declaration through the FDA’s Emergency Use Authorization.
Emergency Waivers for COVID-19 Testing. Executive Order N-25-20, issued just days into the declared emergency on March 12, 2020, waived various statutes and regulations that were found to obstruct the state’s nascent pandemic response efforts. Paragraph nine of the Order consisted of the following provision:
“The certification and licensure requirements of California Code of Regulations, Title 17, section 1079 and Business and Professions Code section 1206.5 are suspended as to all persons who meet the requirements under the Clinical Laboratory Improvement Amendments of section 353 of the Public Health Service Act for high complexity testing and who are performing analysis of samples to test for SARS-CoV-2, the virus that causes COVID-19, in any certified public health laboratory or licensed clinical laboratory.”
This executive order substantially broadened the available workforce for individuals to perform analysis of COVID-19 tests. Because California requirements are considered more restrictive than the federal regulations, laboratories utilizing the waiver have been able to utilize professionals who meet federal standards but who would not currently qualify under Section 1206.5. This increased capacity has been essential to California’s robust response to the COVID-19 pandemic through the proliferation of testing options.
Because Executive Order N-25-20’s authority relied on the active State of Emergency declared by the Governor, it will no longer have the force of law immediately upon the expiration of that declaration. The Governor has stated that the declaration will be terminated on February 28, 2023. However, the formal end of the declared emergency will not mean an end to the need for widely available COVID-19 testing. In his announcement regarding his timeline, the Governor requested statutory changes to ensure “the continued ability of laboratory workers to solely process COVID-19 tests.” This bill would effectuate that request by continuing to waive state requirements for individuals analyzing COVID-19 tests who meet the federal requirements for high complexity testing.
COVID-19 Therapeutics. The FDA has authorized two oral antiviral pills for the treatment of mild-to-moderate COVID-19. Paxlovid, developed by Pfizer, is a combination formulation of two protease inhibitor medications: nirmatrelvir and ritonavirhas. Molnupiravir, developed by Merck & Co., is sold under the brand name Lagevrio. Both therapeutics have been shown to prevent hospitalization or death in high-risk patients with mild to moderate COVID-19.
As antiviral therapeutics for COVID-19 became available at the beginning of 2022, the CDPH and other public health entities have pushed to make those treatments accessible, particularly to high-risk patients. Therapeutics have been made free to all Californians, including the uninsured. COVID-19 therapeutics are most effective when taken within days of a patient developing symptoms, so beginning treatment immediately upon receipt of a positive test is the most efficacious way of prevent a patient’s condition from becoming more severe.
Despite the effectiveness and wide availability of COVID-19 therapeutics, it was reported in 2022 that the antiviral medications were being underutilized, particularly within low-income communities and communities of color. The CDPH issued a health advisory for California healthcare providers urging a low threshold to prescribe COVID-19 therapeutics. The Governor repeatedly stated that his objective was to “remedy ongoing inequities in therapeutics access.”
In May 2022, the CDPH announced that it was upgrading 146 existing testing sites to “Test to Treat” locations where individuals could be seen by a provider and receive a prescription for oral antiviral therapeutics immediately upon testing positive for COVID-19. This initiative was launched as a partnership with OptumServe, a company with existing contracts with the state to provide vaccination and testing site services. The state’s program aligned with the Biden Administration’s national Test to Treat initiative in the National COVID-19 Preparedness Plan.
Test to Treat sites are located in areas where access to insurance and health services is considered lower. Clinics traditionally serving these populations have not historically had the operational workflows required to coordinate access to therapeutics as part of their testing programs. The OptumServe sites offer antigen testing, telehealth prescribing for COVID-positive patients, and on-site Paxlovid and molnupiravir dispensing.
Pharmacy Waivers. In addition to the Governor’s emergency powers under EMSA, the BOP has its own statutory authority to waive provisions of the Pharmacy Law and its implementing regulations. California law provides that “during a declared federal, state, or local emergency, the board may waive application of any provisions of this chapter or the regulations adopted pursuant to it if, in the board’s opinion, the waiver will aid in the protection of public health or the provision of patient care.” This allowed the BOP to quickly waive laws that would have hindered the state’s pandemic response independent of either EMSA or the waiver process established through the Governor’s executive order.
Because a key aspect of the CDPH’s Test to Treat program involves the dispensation of COVID-19 therapeutics, the BOP waived provisions of the Pharmacy Law that would have prohibited those drugs from being stored and dispensed outside of a clinical setting or pharmacy. On April 19, 2022, the BOP issued a limited waiver to the CDPH waiving any statutory restrictions on entities operating a testing site approved by the CDPH to dispense COVID-19 oral therapeutics from state supplies, under the following specified conditions:
- The Approved Site complies with all conditions of the FDA approval or authorization of the COVID-19 Oral Therapeutic issued under an EUA, guidance of the federal Health and Human Services Agency and the FDA, and applicable federal dispensing laws.
- The Approved Site complies with all of the required conditions of any agreement or attestation required to be signed by organizations participating in the federal Program.
- The Approved Site also complies with all guidance and requirements established by CDPH.
The BOP’s waiver also required Test to Treat sites to comply with a series of additional requirements relating to drug container labeling, storage, and recordkeeping. The original waiver was scheduled to expire at the end of 2022; the waiver was subsequently extended on December 5, 2022. However, because the BOP’s waiver authority remains dependent on an actively declared state of emergency, the authority granted by the board to the CDPH is currently set to expire on February 28, 2023 when the State of Emergency is terminated.
The expiry of the BOP’s waiver would mean that patients who receive positive COVID-19 tests at a Test to Treat site would have to be directed to pick up their therapeutics at a nearby pharmacy or through a mail order, which could delay treatment and exacerbate inequities. In light of this, the Governor called in his press release announcing the end of the COVID-19 State of Emergency for statutory changes to preserve “the continued ability of nurses to dispense COVID-19 therapeutics” at Test to Treat sites.
This bill would codify the BOP waiver for purposes of allowing COVID-19 therapeutics such as Paxlovid and molnupiravir to be stored and dispensed at Test to Treat locations. The bill would place into statute the same patient safety requirements as the BOP’s waiver. The provision of the bill related to COVID-19 therapeutic dispending would also be subjected to repeal on January 1, 2024, allowing for the Test to Treat program to continue operating under their existing model through the end of the year.
Prior Related Legislation. AB 2107 (Flora, Chapter 956, Statutes of 2022) authorized a person licensed as a clinical genetic molecular biologist scientist to use molecular biology techniques to perform a clinical laboratory test or examination for the detection of any human disease.
SB 1267 (Pan, Chapter 473, Statutes of 2022), added clinical laboratory geneticist scientists and clinical reproductive biologist scientists to the types of clinical laboratory personnel that are licensed and regulated by the CDPH.
AB 526 (Wood, Chapter 653, Statutes of 2021) authorized both dentists and doctors of podiatric medicine to independently prescribe and administer influenza and COVID-19 vaccines and provided additional authority for dentists to administer rapid point-of-care tests for COVID-19.
ARGUMENTS IN SUPPORT:
Quest Diagnostics supports this bill, writing that the Governor’s executive order relating to clinical laboratory requirements “was critical to the state’s response to the COVID-19 pandemic and enabled the lab community to ensure enough resources were available to support testing demand. Without the flexibility granted by the Executive Order, COVID-19 testing demand would have surpassed lab resources, potentially leaving Californians without timely results to COVID-19 tests which have been key to managing the spread of the virus. Further, there have been no adverse implications to test quality since the Executive Order.”
The California Association of Public Health Laboratory Directors (CAPHLD) also supports this bill. CAPHLD has suggested that the bill be “broadened to include additional outbreaks that may occur in this time period and beyond” through amendments to allow for similar waivers of state requirements for lab analysis of any “communicable disease that is declared a Public Health Emergency” by the CDPH. However, CAPHLD supports this bill regardless of whether that suggested amendment is made to the bill.
ARGUMENTS IN OPPOSITION:
The California Association for Medical Laboratory Technology (CAMLT) opposes this bill. CAMLT writes: “For over 80 years, CAMLT’s professional members and the entire clinical laboratory community have and will continue to work to protect the health and welfare of all Californians. Patient safety has always been our highest priority and lowering laboratory standards would be an unsafe and unsound practice.”
REGISTERED SUPPORT:
California Association of Public Health Laboratory Directors
California Clinical Laboratory Association
Quest Diagnostics
REGISTERED OPPOSITION:
California Association for Medical Laboratory Technology
Analysis Prepared by: Robert Sumner / B. & P. / (916) 319-3301
Discussed in Hearing
Senate Floor
Senate Standing Committee on Business, Professions and Economic Development
Assembly Floor
Assembly Standing Committee on Health
Assembly Standing Committee on Business and Professions
Bill Author
Bill Co-Author(s):